IPSirius SAS, an early stage French immuno-oncology firm, hopes to obtain a clinical trial authorization from the U.K.’s Medicines and Healthcare Regulatory Products Agency next year, to enable it to move its novel therapeutic cancer vaccine into a first-in-human trial in patients with non-small-cell lung cancer.
Pretzel Therapeutics Inc. has patented heterocycle-containing compounds acting as Lon protease homolog, mitochondrial (LONP1) inhibitors. They are reported to be useful for the treatment of cancer, aging, neurodegeneration and metabolic diseases.
Research at Betta Pharmaceuticals Co. Ltd. has led to the identification of new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Aurora kinases, a group of serine/threonine protein family, comprise Aurora A, B and C members and are involved in the regulation of cell division and mitosis. Aurora A overexpression correlates with poor prognosis and is considered a therapeutic target for cancer treatments, although the clinical development of Aurora kinase inhibitors has been so far limited by excessive safety issues.
Menin (MEN1)/MLL interaction inhibitors are reported in a Bala Therapeutics Inc. patent as potentially useful for the treatment of cancer and diabetes.
A Cytosite Biopharma Inc. patent describes prodrugs of granzyme B-targeting compounds reported to be useful as granzyme B-imaging agents for the diagnosis of cancer.
Despite the success of CAR T-cell therapies for cancer immunotherapy, only a small percent of patients have a significant clinical response, and it is difficult to distinguish responders from nonresponders at an early stage with current imaging techniques.
The c-Myc oncogene is overexpressed in a significant proportion of human cancers, including difficult-to-treat triple-negative breast cancers (TNBC). In the pursuit of novel anti-TNBC agents, there is a growing interest in ligands that can stabilize c-Myc promoter G-quadruplex (G4), thereby inhibiting c-Myc expression.
Novel therapeutic strategies are urgently needed to treat glioblastoma, the most aggressive type of primary brain tumor frequently associated with poor survival.
RSS
